Business
FTI Consulting Survey Shows Life Sciences Leaders’ Outlook Tempered by Concerns Around Fundraising, Policy Shifts and Cybersecurity Heading into 2026
Industry Leaders Point to Challenging Political and Economic Environment Key Legislation Expected to Impact Supply Chain and Drug Costs Recent M&A Momentum Offset by Challenging Fundraising Environment Artificial Intelligence (AI) Seen as Key Investment Area WASHINGTON, Dec. 16, 2025 (GLOBE NEWSWIRE) -- FTI Consulting, Inc. (NYSE: FCN) today announced findings from its fifth annual U.S. Healthcare & Life Sciences Industry Outlook 2026, which revealed that leaders are less optimistic about the st
About this update from Fti Consulting, Inc.
[{"type":"image","alt":"FTI Consulting, Inc.","displaySize":"","headline":null,"caption":"FTI Consulting, Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":263,"url":"https://media.zenfs.com/en/globenewswire.com/0e4a03d93964f41f1b9e42098375c4e8"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/SVoKy.08lA2QXR4MQ_9K4w--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTM2ODtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/0e4a03d93964f41f1b9e42098375c4e8","width":300,"height":263}},"lazy":false},{"type":"text","content":"Industry Leaders Point to Challenging Political and Economic Environment","length":72,"tagName":"p"},{"type":"text","content":"Key Legislation Expected to Impact Supply Chain and Drug Costs","length":62,"tagName":"p"},{"type":"text","content":"Recent M&A Momentum Offset by Challenging Fundraising Environment","length":69,"tagName":"p"},{"type":"text","content":"Artificial Intelligence (AI) Seen as Key Investment Area","length":56,"tagName":"p"},{"type":"text","content":"WASHINGTON, Dec. 16, 2025 (GLOBE NEWSWIRE) -- FTI Consulting, Inc. (NYSE: FCN) today announced findings from its fifth annual U.S. Healthcare & Life Sciences Industry Outlook 2026, which revealed that leaders are less optimistic about the state of the industry, down 9% from last year’s survey.","length":298,"tagName":"p"},{"type":"text","content":"The survey indicates that while optimism persists in some areas, industry leaders are navigating significant challenges within the capital markets, evolving political and regulatory landscapes, and have ongoing cybersecurity concerns.","length":234,"tagName":"p"},{"type":"text","content":"“As we look towards 2026, life sciences companies face a complex landscape of shifting financial and regulatory factors, which demand strategic agility,” said Robert Stanislaro, Head of the Healthcare & Life Sciences’ Corporate Reputation offering within FTI Consulting’s Strategic Communications segment. “Organizations that prioritize scenario planning and incorporate those insights, as well as leverage AI to drive efficiencies, into future business plans will be best positioned to navigate the challenges and opportunities ahead.”","length":540,"tagName":"p"},{"type":"text","content":"Policy and Regulatory ChallengesA year into President Trump’s second presidency, life sciences leaders remain divided (...